Cochrane · systematic review · CD013673
Pravastatin for lowering lipids
Adams, SP, Alaeiilkhchi, N, Tasnim, S, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
HypertensionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
5
No studies
1
Included studies
NR
No studies 1 · 16.7%Ungraded 0 · 0%Very low 1 · 16.7%Low 0 · 0%Moderate 2 · 33.3%High 2 · 33.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Effect of pravastatin on low‐density lipoprotein (LDL) cholesterol
Population: participants with normal or abnormal lipid profiles
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
mg/day LDL cholesterol | no estimate extracted | 11 studies · 765 participants | High |
mg/day LDL cholesterol | no estimate extracted | 22 studies · 3117 participants | Moderate Downgraded: inconsistency |
mg/day LDL cholesterol | no estimate extracted | 35 studies · 4869 participants | Moderate Downgraded: inconsistency |
mg/day LDL cholesterol | no estimate extracted | 4 studies · 881 participants | High |
Effect of pravastatin on withdrawals due to adverse effects
Population: participants with normal or abnormal lipid profiles
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pravastatin 10 to 80 mg/day (6 to 156 weeks) | no estimate extracted | NR | No studies |
WDAEs | RR 0.81 [0.63, 1.03] | 33 studies · 6187 participants | Very low Downgraded: risk of bias, imprecision |